- Home
- MCHX vs CUE Comparison
MCHX vs CUE Comparison
Compare MCHX & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCHX
- CUE
- Stock Information
- Founded
- MCHX 2003
- CUE 2014
- Country
- MCHX United States
- CUE United States
- Employees
- MCHX N/A
- CUE N/A
- Industry
- MCHX Business Services
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- MCHX Consumer Discretionary
- CUE Health Care
- Exchange
- MCHX Nasdaq
- CUE Nasdaq
- Market Cap
- MCHX 84.3M
- CUE 77.3M
- IPO Year
- MCHX 2004
- CUE 2018
- Fundamental
- Price
- MCHX $1.92
- CUE $1.31
- Analyst Decision
- MCHX
- CUE Strong Buy
- Analyst Count
- MCHX 0
- CUE 5
- Target Price
- MCHX N/A
- CUE $5.00
- AVG Volume (30 Days)
- MCHX 31.7K
- CUE 406.9K
- Earning Date
- MCHX 03-13-2025
- CUE 03-10-2025
- Dividend Yield
- MCHX N/A
- CUE N/A
- EPS Growth
- MCHX N/A
- CUE N/A
- EPS
- MCHX N/A
- CUE N/A
- Revenue
- MCHX $48,594,000.00
- CUE $9,532,000.00
- Revenue This Year
- MCHX N/A
- CUE $73.11
- Revenue Next Year
- MCHX $4.63
- CUE $11.02
- P/E Ratio
- MCHX N/A
- CUE N/A
- Revenue Growth
- MCHX N/A
- CUE 149.53
- 52 Week Low
- MCHX $1.11
- CUE $0.45
- 52 Week High
- MCHX $2.40
- CUE $2.93
- Technical
- Relative Strength Index (RSI)
- MCHX 48.44
- CUE 52.47
- Support Level
- MCHX $1.88
- CUE $1.21
- Resistance Level
- MCHX $2.13
- CUE $1.75
- Average True Range (ATR)
- MCHX 0.11
- CUE 0.18
- MACD
- MCHX -0.01
- CUE 0.00
- Stochastic Oscillator
- MCHX 46.15
- CUE 45.00
About MCHX Marchex Inc. Class B
Marchex Inc is a conversational analytics and solutions company that helps businesses connect, drive, measure, convert callers into customers, and connect the voice of the customer to their business. It delivers data insights and incorporates artificial intelligence (AI)-powered functionality that drives insights and solutions to help companies find, engage, and support their customers across voice and text-based communication channels. The group enables sales and marketing teams to deliver the buying experiences that today's customers expect. The company generates the majority of its revenues from core analytics and solutions services. The company operates in the United States, Canada, and other countries.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.